Tremfya is the first and only fully-human, dual-acting IL-23p19 subunit inhibitor approved in both ulcerative colitis and ...

Promising results of MSC therapy have been obtained in patients with severe graft versus host disease of the gut. Our objective was to determine the safety and feasibility of autologous bone marrow ...

Data from the Phase IIIb APEX study, presented at EULAR 2025, show that guselkumab (Tremfya) improved joint and skin symptoms and inhibited structural joint damage in patients with active psoriatic ...

Expert Rev Gastroenterol Hepatol. 2010;4(2):167-180. Expert Rev Gastroenterol Hepatol. 2010;4(2):167-180. © 2010 Expert Reviews Ltd. Cite this: What is the Optimal ...

June 6 (Reuters) - Otsuka's (4578.T), opens new tab experimental therapy for a potentially life-threatening kidney disease more than halved severe levels of protein in the urine of patients ...

CINCINNATI (WKRC) - The Crohn’s & Colitis Foundation’s largest, most impactful fundraising event takes place June 7. UC gastroenterologist Dr. Susan Kais and Emily Scott, a UC gastroenterology ...

The ACG has released new clinical guidelines for the management of ulcerative colitis and Crohn’s disease in adult patients.The guidelines, published in The American Journal of Gastroenterology, ...

Findings on intestinal ultrasound (IUS) are useful for predicting remission in recent-onset Crohn’s disease (CD), a prospective, population-based cohort of newly diagnosed patients in Denmark ...

No significant differences were observed with guselkumab treatment long-term among patients ... The mean age was 52 years, 60.4% were men, and the mean disease duration was 22 years. Almost ...

Iluzanebart, a monoclonal antibody TREM2 agonist, was being developed by Vigil for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare, progressive brain disease ...